Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2020

01-08-2020 | Breast Cancer | Editorial

The bottom line for lesion localization in breast cancer

Author: M. Ahmed

Published in: Breast Cancer Research and Treatment | Issue 3/2020

Login to get access

Abstract

The development of radioisotope-independent, wire-free localization techniques for excision of non-palpable breast cancer will continue to expand rapidly within the next few years, increasing market competition. It is imperative that the introduction of these new technologies is correctly evaluated in terms of their major logistical benefits in streamlining pathways from radiology to the operating theatre and subsequent financial savings, rather than focusing upon margin re-excision rates—in which they are unlikely to advance current practice.
Literature
1.
Ahmed M, van Hemelrijck M, Douek M (2013) Systematic review of radioguided versus wire-guided localization in the treatment of non-palpable breast cancers. Breast Cancer Res Treat 140(2):241–252CrossRefPubMed
2.
Postma EL, Verkooijen HM, van Esser S, Hobbelink MG, van der Schelling GP, Koelemij R, Witkamp AJ, Contant C, van Diest PJ, Willems SM, Borel Rinkes IH, van den Bosch MA, Mali WP, van Hillegersberg R (2012) (2012) Group Rs Efficacy of 'radioguided occult lesion localisation' (ROLL) versus 'wire-guided localisation' (WGL) in breast conserving surgery for non-palpable breast cancer: a randomised controlled multicentre trial. Breast Cancer Res Treat 136(2):469–478CrossRefPubMed
3.
Srour MK, Kim S, Amersi F, Giuliano AE, Chung A (2020) Comparison of wire localization, radioactive seed, and Savi scout((R)) radar for management of surgical breast disease. Breast J 26(3):406–413CrossRefPubMed
4.
Ahmed M, Wood S, Leff D (2019) An evaluation of access to critical breast oncoplastic patient information within a regional autologous free-flap reconstruction service. Ecancermedicalscience 13:92CrossRef
5.
Scotland PH. Data and intelligence - Theatres. 2019.
6.
Marcus RK, Lillemoe HA, Caudle AS, Weinberg JS, Gidley PW, Skibber JM, Levenback CF, Swisher SG, Aloia TA (2019) Facilitation of surgical innovation: is it possible to speed the introduction of new technology while simultaneously improving patient safety? Ann Surg 270(6):937–941CrossRefPubMed
7.
Hirst A, Philippou Y, Blazeby J, Campbell B, Campbell M, Feinberg J, Rovers M, Blencowe N, Pennell C, Quinn T, Rogers W, Cook J, Kolias AG, Agha R, Dahm P, Sedrakyan A, McCulloch P (2019) No surgical innovation without evaluation: evolution and further development of the IDEAL framework and recommendations. Ann Surg 269(2):211–220CrossRefPubMed
8.
Garas G, Cingolani I, Panzarasa P, Darzi A, Athanasiou T (2017) Network analysis of surgical innovation: measuring value and the virality of diffusion in robotic surgery. PLoS ONE 12(8):e0183332CrossRefPubMedPubMedCentral
Metadata
Title
The bottom line for lesion localization in breast cancer
Author
M. Ahmed
Publication date
01-08-2020
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-020-05735-x

Other articles of this Issue 3/2020

Breast Cancer Research and Treatment 3/2020 Go to the issue

Epidemiology

Breast-contour preserving procedures for early-stage breast cancer: a population-based study of the trends, variation in practice and predictive characteristics in Denmark and the Netherlands

Epidemiology

A 15-year follow-up study on long-term adherence to health behaviour recommendations in women diagnosed with breast cancer

Review

The influence of mastectomy and reconstruction on residual upper limb function in breast cancer survivors

Epidemiology

Impact of chemotherapy, radiotherapy, and endocrine therapy on sick leave in women with early-stage breast cancer during a 5-year period: a population-based cohort study

Editorial

Breast cancer care during a pandemic: an opportune time for cryoablation?

Review

Meta-analysis of prepectoral implant-based breast reconstruction: guide to patient selection and current outcomes
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits